Cyclerion Therapeutics
CYCN
15 hedge funds and large institutions have $3.42M invested in Cyclerion Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
4% less capital invested
Capital invested by funds: $3.59M → $3.42M (-$161K)
4.19% less ownership
Funds ownership: 43.68% → 39.49% (-4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.63K |
| 2 |
TCP
Tyndall Capital Partners
New York
|
+$1.11K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$946 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$105 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$70 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.39K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.67K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$626 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPC
1
Slate Path Capital
New York
| $1.15M | – | – | – |
|
|
MP
2
MFN Partners
Boston,
Massachusetts
| $542K | – | – | – |
|
|
TCP
3
Tyndall Capital Partners
New York
| $527K | +$1.11K | +348 | +0.2% |
|
|
4
Fidelity Investments
Boston,
Massachusetts
| $519K | -$1.67K | -522 | -0.3% |
|
|
AG
5
Artal Group
Luxembourg
| $445K | – | – | – |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $103K | +$2.63K | +823 | +3% |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $75.2K | – | – | – |
|
8
BlackRock
New York
| $54.9K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $8.08K | +$946 | +296 | +13% |
|
|
10
Morgan Stanley
New York
| $2.08K | -$2.39K | -747 | -54% |
|
11
Group One Trading
Chicago,
Illinois
| $1.73K | – | – | – |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$70 | +22 | +7% |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $106 | +$105 | +33 | New |
|
14
Wells Fargo
San Francisco,
California
| $48 | – | – | – |
|
15
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $3 | – | – | – |
|
|
16
Osaic Holdings
Scottsdale,
Arizona
| – | -$626 | -187 | Closed |
|
CYCN Hedge Fund Activity: Q1 2024 in Review
15 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2024, worth a combined $3.42M — down 4.5% from $3.59M a quarter earlier.
Fund positioning in CYCN was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $2.63K. The largest seller was Morgan Stanley, cutting an estimated $2.39K.
- 15 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $3.42M of Cyclerion Therapeutics stock for Q1 2024, down 4.5% quarter-over-quarter.
- 1 fund opened new Cyclerion Therapeutics positions in Q1 2024 and 1 closed out, a net change of 0 holders.
- The largest Cyclerion Therapeutics buyer in Q1 2024 was Geode Capital Management, an estimated $2.63K added.
- The largest Cyclerion Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $2.39K sold.
Based on aggregated 13F filings for Q1 2024.